top of page
Search

Where Can I Get Immunotherapy Treatment for Non-Small Cell Lung Cancer in India?

Writer: Ganesh Akunoori
Ganesh Akunoori
11 minutes ago
9 min read

Introduction

Your relative’s biopsy just confirmed non-small cell lung cancer (NSCLC), and someone mentioned immunotherapy. Now you are staring at a search bar, trying to separate genuine treatment pathways from noise.

The good news is that immunotherapy for NSCLC is definitely available in India right now, using globally approved drugs like pembrolizumab, nivolumab, and atezolizumab. The hard truth is that this form of cancer treatment is concentrated heavily in a handful of major metropolitan cities. Access means navigating a matrix of mandatory biomarker testing, significant out-of-pocket costs because public schemes largely exclude these drugs, and selecting a center equipped to handle complex immune side effects. The hospital must be capable of managing the full arc of care.

This article maps out exactly where to find treatment, how to qualify for it, and what it will cost your family.

Key Takeaways

Before you book a single consultation, these are the four non-negotiable realities of pursuing immunotherapy for NSCLC in India.

  • Treatment hubs are metropolitan: Accessible centers are overwhelmingly in Mumbai, Delhi, Bangalore, Chennai, and Hyderabad. Planning for travel or temporary relocation is often unavoidable.

  • Biomarker testing is mandatory: You cannot bypass a tissue biopsy for a PD-L1 Tumor Proportion Score (TPS), a process that imposes a critical 10 to 14 day waiting period before any drug is administered.

  • Financial planning must be aggressive: While some transparent packages exist from private practitioners, per-cycle drug costs still run from ₹1.5 lakh to ₹3 lakh, and a full two-year course demands a financial strategy from day one.

  • Team structure determines safety: The single most important factor in choosing a hospital is the presence of a thoracic-specific tumor board and an ICU capable of managing immune-related adverse events.

  • That last point deserves immediate attention.

  • A thoracic tumor board coordinates your pulmonologist, medical oncologist, radiation oncologist, pathologist, and radiologist around one table before a single cycle begins. When your immune system overreacts to a checkpoint inhibitor, you need intensivists who have managed cytokine release syndrome and pneumonitis before. The difference between a general ICU and one attached to a lung cancer program is concrete: one team recognizes immune-related pneumonitis on day two, the other treats it as an infection for a week first. Ask any prospective center whether their tumor board meets weekly with thoracic radiology and pathology present, and whether their intensivists have a protocol for Grade 3+ immune-related adverse events.

  • As for the financial piece, the ₹1.5 lakh to ₹3 lakh per-cycle figure is the drug cost alone from private practitioners who disclose their pricing. It does not include hospital admission charges, pre-infusion blood work, or managing side effects that require inpatient care. Build your budget so the two-year commitment works at the highest plausible cost, because a treatment interruption from a funding gap is dangerous with checkpoint inhibitors.

What Immunotherapy for NSCLC Means and Where It’s Available in India

Immunotherapy for NSCLC does not attack the cancer directly. Instead, it disables a shield that cancer cells use to hide from your body’s own immune system. Immune checkpoint inhibitors, specifically those targeting the PD-1 or PD-L1 proteins, are designed to reactivate your T-cells so they can recognize and destroy lung cancer cells. To say it another way: these drugs take the brakes off your immune system. The central drugs regulatory authority, CDSCO, has approved three primary agents in this class for use in India: pembrolizumab, nivolumab, and atezolizumab.

The practical limitation is geography. Immunotherapy administration for lung cancer is not evenly spread across the country; it is a capability clustered in thorough cancer centers. The table below maps the specific cities and the types of institutions where you will find this treatment.

City

Representative Hospitals

Type of Institution

Mumbai

Tata Memorial Hospital, P.D. Hinduja Hospital

Government-subsidized and private tertiary care

Delhi

AIIMS, Rajiv Gandhi Cancer Institute

Government apex center and private specialty center

Bangalore

HCG Hospitals, Apollo Hospitals

Comprehensive private cancer networks

Chennai

Cancer Institute (Adyar), Apollo Proton Centre

Charitable trust hospital and advanced private care

Hyderabad

Dr. Bharat Patodiya’s daycare facility

Subspecialist private oncology practice with daycare

Outside of these listed hubs, and a few other locations, infusion centers are extremely limited. Tier-2 cities largely lack both the molecular pathology labs for testing and the dedicated medical oncology teams experienced in managing these novel toxicities.

How to Start: The Biomarker-Testing Prerequisite

Do not start immunotherapy until these diagnostic steps are complete. This is the point at which treatment timelines either hold firm or collapse. The gateway is a tissue biopsy sent for PD-L1 immunohistochemistry (IHC). The lab pathologist examines the tumor sample and returns a Tumor Proportion Score (TPS), a percentage that expresses how many of your cancer cells exhibit the PD-L1 protein. Only a high TPS typically qualifies you for single-agent immunotherapy as a first line, and you will wait approximately 10 to 14 days for the complete molecular profile.

That waiting period is draining, but it is non-negotiable. Giving immunotherapy to a patient with a specific genetic driver mutation, specifically an EGFR or ALK alteration, can be ineffective and dangerous. If your diagnosis is non-squamous NSCLC, your oncologist must confirm you are negative for these mutations before proceeding.

Recent regulatory activity reinforces this rule: in July 2026, a CDSCO expert committee reviewing a Phase III trial for atezolizumab explicitly conditioned permission on requiring EGFR/ALK negativity for every subject in the study.

Skipping these tests in a bid to start treatment faster is the single most dangerous error a family can push for. Immunotherapy in the presence of driver oncogenes may represent lost time and toxicity without benefit. You are aiming to prove your tumor is a biological match for the drug.

The Cost of Immunotherapy for NSCLC in India and Financial Planning

The financial reality is the sharpest edge of this therapy.

  • Per-cycle costs: Pembrolizumab costs roughly ₹2.5 lakh to ₹3 lakh per cycle; other checkpoint inhibitors in the class bring the lower range to about ₹1.5 lakh per cycle.

  • Annual drug burden: On a standard two-week schedule, the projected drug burden stretches from ₹35 lakh to ₹50 lakh annually, and oncologists typically plan for up to two years of continuous therapy in patients who respond.

  • Insurance reality: Ayushman Bharat PM-JAY generally excludes immunotherapy for NSCLC; partial reimbursement may exist under specific private corporate policies, but verify this meticulously.

  • Practical budgeting: Transparent private packages that bundle drug and supportive care costs, starting from about ₹2.5 lakh to ₹8 lakh, become a practical budgeting tool for families self-financing treatment.

Specific Drugs and How They Are Administered

The three CDSCO-approved checkpoint inhibitors for this disease are pembrolizumab (brand name Keytruda), nivolumab (brand name Opdivo), and atezolizumab (brand name Tecentriq). All three inhibit the pathway cancer cells use to evade immune detection, but they target slightly different protein interactions on the T-cell or tumor cell surface.

Historically, receiving these drugs meant sitting in a chemotherapy daycare suite for a standard intravenous infusion lasting an hour or more every few weeks. That is changing fast. Nivolumab and atezolizumab are now available as quick subcutaneous injections, a delivery method that slashes administration time dramatically.

Instead of a prolonged IV drip, you receive a pre-measured injection under the skin. The visit converts into a far shorter, less draining appointment. For patients facing long treatment timelines, this is a fundamental quality-of-life upgrade.

Selecting a Treatment Center and the Power of a Multidisciplinary Team

You are looking for an ecosystem with the infrastructure to rescue you if your immune system attacks a healthy organ. Here are the non-negotiable selection criteria to verify before you commit to a treatment center.

  • On-site molecular pathology lab: The center must handle PD-L1 IHC and EGFR/ALK testing internally to avoid the specimen transport delays that fracture an already tight 10 to 14 day testing window.

  • Dedicated thoracic tumor board: You need a medical oncologist, a radiation oncologist, and a pulmonary medicine specialist reviewing your case together.

  • ICU equipped for immunotoxicities: The facility must have an intensive care unit with documented experience managing pneumonitis, severe colitis, and cytokine release syndrome, since these immune-related adverse events can escalate within hours.

  • Financial counseling desk: The center should verify your government scheme eligibility and coordinate charitable aid applications. This function is critical when a single treatment cycle costs over ₹2 lakh.

Beyond the Infusion: Supportive Care and Patient Coordination

The drug alone is not the treatment program. It is the tool; the wraparound services are what keep you on it for two years.

Top-tier oncology groups in India now structure immunotherapy delivery within a broader supportive care framework because patients who abandon treatment usually do so from cumulative side-effect misery, not disease progression. These programs include nutrition and dietetics to maintain your weight through taste changes, psycho-oncology for the mental health burden of a chronic cancer treatment, and dedicated pain and palliative care teams that intervene early rather than only at the end of life. A practical example is the availability of certified home-based chemotherapy nursing teams, which can move stable maintenance infusions to your living room where clinically appropriate. These logistics separate a fragmented treatment journey from a navigable one.

Regulatory Updates and 2026 Research Shaping NSCLC Immunotherapy

India's drug regulator is making domestic manufacturers earn their NSCLC immunotherapy labels. In a July 2026 meeting, the CDSCO's Subject Expert Committee deferred Zydus Lifesciences' proposal to add extrapolated indications for nivolumab. The committee wants the firm to submit compliance data from a previously mandated Phase IV clinical study in locally advanced or metastatic NSCLC first. The regulator is demanding India-specific safety data before broadening the drug's permitted uses.

At the same time, researchers globally are asking why immunotherapy fails in some NSCLC patients and succeeding in others. The investigation centers on co-mutations. When a tumor carries KRAS alongside alterations in STK11 or KEAP1, the combination appears to produce primary resistance to checkpoint inhibitors, independent of PD-L1 expression levels. Broad molecular profiling at diagnosis is how your oncologist hedges against these known resistance pathways.

One therapy families frequently ask about, CAR-T, is currently irrelevant to NSCLC. The CDSCO-approved product NexCAR19, greenlit in October 2023, and other cellular therapies are restricted to hematologic malignancies like lymphomas and leukemias. Solid tumor application for lung cancer remains investigational and inaccessible in standard Indian clinical practice as of now.

Conclusion

Immunotherapy for non-small cell lung cancer in India works when you get three things right. First, secure the biomarker test before anyone schedules an infusion, the test determines whether you are even a candidate. Second, choose a multidisciplinary center in a major metro where the team can spot and manage immune-related toxicity early. Third, walk in with a clear financial plan. Each cycle costs ₹1.5 lakh to ₹3 lakh, and that math needs to sit on the table from day one.

Cost is still the hardest barrier for most families. Biosimilar entrants and private-package pricing are beginning to change that arithmetic for patients who qualify on biomarker grounds, though progress is uneven across cities.

You control the sequence. Get the test. Find the right center. Price the full course. That order protects you from the two biggest mistakes in Indian immunotherapy care: proceeding without a targetable mutation and chasing a drug you cannot sustain through the full protocol.

Frequently Asked Questions

What are the major hospitals and oncology centers in India that offer immunotherapy for non-small cell lung cancer?

Accessible immunotherapy for NSCLC is concentrated in major metropolitan hubs.

  • Mumbai: Tata Memorial Hospital and P.D. Hinduja Hospital lead the options.

  • Delhi: AIIMS and Rajiv Gandhi Cancer Institute serve the region.

  • Bangalore: HCG and Apollo are primary providers.

  • Chennai: The Cancer Institute (Adyar) and Apollo Proton Centre offer thorough programs.

  • Tier-2 cities: Access remains severely limited.

What is the actual cost of immunotherapy for NSCLC in India per cycle?

Per-cycle costs range from ₹1.5 lakh to ₹3 lakh depending on the drug.

  • Pembrolizumab: The most expensive, typically costing ₹2.5 lakh to ₹3 lakh per cycle.

  • Nivolumab and atezolizumab: Form the lower end near ₹1.5 lakh.

  • Annual projection: When factoring in a two-week treatment cycle, the projected annual drug-only cost lands between ₹35 lakh and ₹50 lakh.

Is immunotherapy for lung cancer covered under the Ayushman Bharat scheme?

No, Ayushman Bharat PM-JAY generally excludes immunotherapy for non-small cell lung cancer.

  • Coverage limit: Despite providing a ₹5 lakh annual coverage envelope, these high-cost checkpoint inhibitors are not on the scheme’s formulary for this indication.

  • Payment options: You must rely on out-of-pocket payment, specific private insurance policies that explicitly cover immunotherapy, or negotiated transparent packages.

What biomarker test is mandatory before starting immunotherapy for NSCLC?

A tissue biopsy for PD-L1 immunohistochemistry (IHC) is mandatory. The test returns a Tumor Proportion Score (TPS) to determine if your cancer is likely to respond. You must not start treatment without this result. For non-squamous NSCLC, confirming that you are negative for EGFR and ALK genetic mutations is also key to avoid primary treatment resistance.

How long does it take to get the PD-L1 test results back before starting treatment?

Expect a waiting period of approximately 10 to 14 days for the complete molecular profile to be returned. This includes both the PD-L1 IHC staining and, where necessary, the genomic profiling for EGFR and ALK. Rushing to start without this data is not medically safe, as it risks administering an ineffective and potentially harmful treatment.

Can you get immunotherapy as a quick injection instead of a long IV infusion in India?

Yes. While pembrolizumab continues to be given as a standard intravenous infusion, both nivolumab and atezolizumab are now available in India as quick subcutaneous injections. This formulation allows the medication to be delivered under the skin in a few minutes instead of an hour-long drip, significantly reducing the time you spend in the chemotherapy daycare suite.

Sources

 
 
 

Comments

bottom of page